• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic delivery >Review of subcutaneous interferon beta-1a, delivered via the electronic self-injection device RebiSmart, for the treatment of multiple sclerosis
【24h】

Review of subcutaneous interferon beta-1a, delivered via the electronic self-injection device RebiSmart, for the treatment of multiple sclerosis

机译：通过电子自动注射设备RebiSmart输送的皮下干扰素beta-1a的综述，用于治疗多发性硬化症

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Multiple sclerosis (MS) is a chronic progressive demyelinating disease of the central nervous system that can present with a wide range of debilitating psychological and physical symptoms [l]. The worldwide prevalence of MS is estimated at more than 2.1 million people [101] and the average age of onset for the disease is approximately 30 years [2].Although MS is currently incurable, treatment with some disease-modifying drugs (DMDs) is indicated to reduce the frequency of exacerbations (relapses) and, in addition, interferon (IFN) (3-la is indicated to delay the accumulation of disability over time, both of which are common features of the disease [3-6]. Current evidence suggests that these DMDs result in better clinical outcomes if they are initiated early in the course of MS compared with delayed initiation [7].
机译：多发性硬化症（MS）是中枢神经系统的一种慢性进行性脱髓鞘疾病，可表现出多种使人衰弱的心理和身体症状[1]。据估计，全球范围内MS的患病率超过210万人[101]，该病的平均发病年龄约为30岁[2]。尽管目前尚无法治愈MS，但仍可以使用某些疾病缓解药物（DMD）治疗表示可以减少病情加重（复发）的频率，此外，干扰素（IFN-α）（3-1a表示可以随着时间的推移延迟残疾的积累，这两种疾病都是该病的共同特征[3-6]。有证据表明，与延迟启动相比，这些DMD如果在MS过程中早期启动，将产生更好的临床结果[7]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号